Treatment of obsessive-compulsive disorders with 5-HT.sub.2 antagonists
    7.
    发明授权
    Treatment of obsessive-compulsive disorders with 5-HT.sub.2 antagonists 失效
    用5-HT2拮抗剂治疗强迫症

    公开(公告)号:US5618824A

    公开(公告)日:1997-04-08

    申请号:US209084

    申请日:1994-03-09

    CPC分类号: A61K31/445

    摘要: The present invention is directed to 5-HT.sub.2 antagonists and their use as agents in the treatment of obsessive-compulsive disorders (OCD). The invention is particularly directed to the compound (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol which is a member of a class of 5-HT.sub.2 antagonists known as N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5-HT.sub.2 receptor site.

    摘要翻译: 本发明涉及5-HT2拮抗剂及其作为治疗强迫症(OCD)的药物的用途。 本发明特别涉及作为一类5-HT2拮抗剂的成员的化合物(+) - α-(2,3-二甲氧基苯基)-1- [2-(4-氟苯基)乙基] -4-哌啶甲醇 称为N-芳烷基哌啶甲醇衍生物,其是5-羟色胺在5-HT2受体位点结合的有效和选择性抑制剂。